Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling

American Journal of Hypertension

Volumn 24, Issue 5, 2011, Pages 550-556

  Inaba, Shinji ^a   Iwai, Masaru ^a   Furuno, Megumi ^a   Kanno, Harumi ^a   Senba, Izumi ^a   Okayama, Hideki ^a   Mogi, Masaki ^a   Higaki, Jitsuo ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiotensin II receptor; blood pressure; hypertension; inflammation; oxidative stress; prehypertension; transgenic mouse; vascular remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; HYDRALAZINE; POLYETHYLENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; SUPEROXIDE; VALSARTAN; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKENING; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL INJURY; CONTROLLED STUDY; CUFF; FEMORAL ARTERY; GENE OVEREXPRESSION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PREHYPERTENSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; ANIMAL; ARTERY; BLOOD VESSEL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GENETICS; NEOINTIMA; PATHOLOGY; PHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINOGEN; ANIMALS; ARTERIES; BLOOD VESSELS; DISEASE MODELS, ANIMAL; HYDRALAZINE; HYPERTENSION; MICE; MICE, INBRED C57BL; NADPH OXIDASE; NEOINTIMA; OXIDATIVE STRESS; RENIN; TETRAZOLES; VALINE;

EID: 79954824371     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2011.6     Document Type: Article

References (24)

1. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F Bsen H Kristiansson K Lederballe-Pedersen O Lindholm LH Nieminen MS Omvik P Oparil S Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in h pertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
2. Mochizuki S Dahlöf B Hizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yam K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N; Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439. (Pubitemid 46635780)
3. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y Is prehypertension a risk factor for cardiovascular diseases? Stroke 2005; 36:1859-1863. (Pubitemid 41266514)
4. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, LaCroix AZ, Black HR; Women's Health Initiative Investigators. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007; 115:855-860. (Pubitemid 46294726)
5. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685-1697.
6. Baumann M, Janssen BJ, Hermans JJ, Peutz-Kootstra C, Witzke O, Smits JF, Struijker Boudier HA. Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 2007; 25:207-215. (Pubitemid 44885683)
7. Ishiguro K, Hayashi K, Sasamura H, Sakamaki Y, Itoh H. "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension. Hypertension 2009; 53:83-89.
8. Baumann M, Megens R, Bartholome R, Dolff S, van Zandvoort MA, Smits JF, Struijker-Boudier HA, De Mey JG. Prehypertensive renin-angiotensin-aldosterone system blockade in spontaneously hypertensive rats ameliorates the loss of ong-term vascular function. Hypertens Res 2007; 30:853-861. (Pubitemid 47578248)
9. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K, Murakami K. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 1993; 268:11617-11621. (Pubitemid 23168109)
10. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, Mogi M, Higaki J, Horiuchi M. Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes. Stroke 2009; 40:597-603.
11. Inaba S, Iwai M, Furuno M, Tomono Y, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 2009; 53:356-362.
12. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, Mogi M, Higaki J, Horiuchi M. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am J Hypertens 2009; 22:145-150.
13. Szöcs K, Lassègue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griendling KK. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002; 22:21-27. (Pubitemid 34076227)
14. Manios E, Tsivgoulis G, Koroboki E, Stamatelopoulos K, Papamichael C, Toumanidis S, Stamboulis E, Vemmos K, Zakopoulos N. Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke 2009; 40:1515-1518.
15. Nishijo N, Takamine S, Sugiyama F, Kimoto K, Taniguchi K, Horiguchi H, Ogata T, Murakami K, Fukamizu A, Yagami K. Vascular remodeling in hypertensive transgenic mice. Exp Anim 1999; 48:203-208. (Pubitemid 129558687)
16. Kai T, Shimada S, Kurooka A, Takenaka T, Ishikawa K. Tissue angiotensin concentration in the heart and kidneys in transgenic Tsukuba hypertensive mice. Blood Press 1998; 7:61-63. (Pubitemid 28137528)
17. Wei Y, Whaley-Connell AT, Chen K, Habibi J, Uptergrove GM, Clark SE, Stump CS, Ferrario CM, Sowers JR. NADPH oxidase contributes to vascular inflammation, nsulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50:384-391. (Pubitemid 47205789)
18. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38:581-587.
19. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice J Hypertens 2004; 22:535-542. (Pubitemid 38368487)
20. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res 2007; 101:441-454. (Pubitemid 47347875)
21. Gao YJ, Yang LF, Stead S, Lee RM. Flow-induced vascular remodeling in the mesenteric artery of spontaneously hypertensive rats. Can J Physiol Pharmacol 2008; 86:737-744.
22. Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, Zhao Q, Nishida K, Takeshita A, Egashira K. Monocyte chemoattractant protein-1 is an essentia nflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24:534-539. (Pubitemid 38326149)
23. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit J Biol Chem 2003; 278: 12094-12100. (Pubitemid 36800187)
24. Dikalova A, Clempus R, Lassègue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HH, Owens GK, Lambeth JD, Griendling KK. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112:2668-2676. (Pubitemid 41532604)